211 related articles for article (PubMed ID: 29296529)
1. The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.
Schürch CM; Forster S; Brühl F; Yang SH; Felley-Bosco E; Hewer E
Oncoimmunology; 2017; 7(1):e1373235. PubMed ID: 29296529
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
3. Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Sun J; Muz B; Alhallak K; Markovic M; Gurley S; Wang Z; Guenthner N; Wasden K; Fiala M; King J; Kohnen D; Salama NN; Vij R; Azab AK
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012878
[TBL] [Abstract][Full Text] [Related]
4. YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.
von Ofen AJ; Thiel U; Eck J; Gassmann H; Thiede M; Hauer J; Holm PS; Schober SJ
Front Oncol; 2024; 14():1304374. PubMed ID: 38357194
[TBL] [Abstract][Full Text] [Related]
5. Don't eat me/eat me signals as a novel strategy in cancer immunotherapy.
Khalaji A; Yancheshmeh FB; Farham F; Khorram A; Sheshbolouki S; Zokaei M; Vatankhah F; Soleymani-Goloujeh M
Heliyon; 2023 Oct; 9(10):e20507. PubMed ID: 37822610
[TBL] [Abstract][Full Text] [Related]
6. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
[TBL] [Abstract][Full Text] [Related]
7. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
8. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
[TBL] [Abstract][Full Text] [Related]
9. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.
Feng M; Chen JY; Weissman-Tsukamoto R; Volkmer JP; Ho PY; McKenna KM; Cheshier S; Zhang M; Guo N; Gip P; Mitra SS; Weissman IL
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2145-50. PubMed ID: 25646432
[TBL] [Abstract][Full Text] [Related]
10. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE; He Y; Schepel I; Hendriks MAJM; Wiersma VR; van Ginkel RJ; van Meerten T; Ammatuna E; Huls G; Samplonius DF; Helfrich W; Bremer E
Oncoimmunology; 2018; 7(2):e1386361. PubMed ID: 29308308
[TBL] [Abstract][Full Text] [Related]
11. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
12. Improving nanochemoimmunotherapy efficacy by boosting "eat-me" signaling and downregulating "don't-eat-me" signaling with
Pang G; Wei S; Zhao J; Wang FJ
J Mater Chem B; 2023 Dec; 11(48):11562-11577. PubMed ID: 37982298
[TBL] [Abstract][Full Text] [Related]
13. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma.
Liu X; Zhang H; Wang C; Li Z; Zhu Q; Feng Y; Fan J; Qi S; Wu Z; Liu Y
Curr Neuropharmacol; 2023; 21(10):2159-2173. PubMed ID: 37171006
[TBL] [Abstract][Full Text] [Related]
14. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
15. The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
Brightwell RM; Grzankowski KS; Lele S; Eng K; Arshad M; Chen H; Odunsi K
Gynecol Oncol; 2016 Nov; 143(2):393-397. PubMed ID: 27569584
[TBL] [Abstract][Full Text] [Related]
16. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.
Bruns H; Bessell C; Varela JC; Haupt C; Fang J; Pasemann S; Mackensen A; Oelke M; Schneck JP; Schütz C
Clin Cancer Res; 2015 May; 21(9):2075-83. PubMed ID: 25593301
[TBL] [Abstract][Full Text] [Related]
17. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
18. Regulation of CD47 expression in cancer cells.
Huang CY; Ye ZH; Huang MY; Lu JJ
Transl Oncol; 2020 Dec; 13(12):100862. PubMed ID: 32920329
[TBL] [Abstract][Full Text] [Related]
19. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells.
Li F; Lv B; Liu Y; Hua T; Han J; Sun C; Xu L; Zhang Z; Feng Z; Cai Y; Zou Y; Ke Y; Jiang X
Oncoimmunology; 2018; 7(2):e1391973. PubMed ID: 29308321
[TBL] [Abstract][Full Text] [Related]
20. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
